BR112017026928A2 - uso de um inibidor de acetilcolinesterase e idalopirdina para redução de quedas em pacientes com doença de parkinson - Google Patents

uso de um inibidor de acetilcolinesterase e idalopirdina para redução de quedas em pacientes com doença de parkinson

Info

Publication number
BR112017026928A2
BR112017026928A2 BR112017026928-7A BR112017026928A BR112017026928A2 BR 112017026928 A2 BR112017026928 A2 BR 112017026928A2 BR 112017026928 A BR112017026928 A BR 112017026928A BR 112017026928 A2 BR112017026928 A2 BR 112017026928A2
Authority
BR
Brazil
Prior art keywords
disease
patients
idalopirdine
acetylcholinesterase
parkinson
Prior art date
Application number
BR112017026928-7A
Other languages
English (en)
Other versions
BR112017026928B1 (pt
Inventor
E. M. De Jong Inge
Kucinski Aaron
Sarter Martin
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BR112017026928A2 publication Critical patent/BR112017026928A2/pt
Publication of BR112017026928B1 publication Critical patent/BR112017026928B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se relaciona com o uso de um inibidor de acetilcolinesterase e idalopirdina para redução das quedas em pacientes sofrendo de uma doença do snc, em particular pacientes com doença de parkinson, em que o equilíbrio, marcha ou movimento é prejudicado.
BR112017026928-7A 2016-04-26 2017-04-25 Uso de idalopirdina em combinação com um inibidor de acetilcolinesterase BR112017026928B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600248 2016-04-26
DKPA201600248 2016-04-26
PCT/EP2017/059739 WO2017186686A1 (en) 2016-04-26 2017-04-25 Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Publications (2)

Publication Number Publication Date
BR112017026928A2 true BR112017026928A2 (pt) 2018-08-14
BR112017026928B1 BR112017026928B1 (pt) 2023-04-11

Family

ID=58632402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026928-7A BR112017026928B1 (pt) 2016-04-26 2017-04-25 Uso de idalopirdina em combinação com um inibidor de acetilcolinesterase

Country Status (27)

Country Link
US (1) US10383849B2 (pt)
EP (1) EP3448430B1 (pt)
JP (1) JP6992004B2 (pt)
KR (1) KR102473545B1 (pt)
CN (1) CN109069650A (pt)
AU (1) AU2017256623B2 (pt)
BR (1) BR112017026928B1 (pt)
CA (1) CA3020557C (pt)
CL (1) CL2018003013A1 (pt)
CY (1) CY1126138T1 (pt)
DK (1) DK3448430T3 (pt)
ES (1) ES2949288T3 (pt)
FI (1) FI3448430T3 (pt)
HR (1) HRP20230693T8 (pt)
HU (1) HUE062626T2 (pt)
IL (1) IL262546B (pt)
LT (1) LT3448430T (pt)
MX (1) MX2018013031A (pt)
PL (1) PL3448430T3 (pt)
PT (1) PT3448430T (pt)
RS (1) RS64307B1 (pt)
RU (1) RU2742173C2 (pt)
SG (1) SG11201809297UA (pt)
SI (1) SI3448430T1 (pt)
TW (1) TW201806621A (pt)
WO (1) WO2017186686A1 (pt)
ZA (1) ZA201806864B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909895UA (en) * 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
JP2021515801A (ja) * 2017-12-22 2021-06-24 ニューロセア，エルエルシー 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
DK1379239T3 (da) * 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
WO2006107860A2 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
US20100120747A1 (en) * 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
RU2393158C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
HRP20230693T1 (hr) 2023-10-13
JP2019519480A (ja) 2019-07-11
SI3448430T1 (sl) 2023-08-31
DK3448430T3 (da) 2023-07-03
LT3448430T (lt) 2023-07-25
US10383849B2 (en) 2019-08-20
TW201806621A (zh) 2018-03-01
HUE062626T2 (hu) 2023-11-28
HRP20230693T8 (hr) 2023-11-10
CY1126138T1 (el) 2023-11-15
CL2018003013A1 (es) 2018-12-14
RU2742173C2 (ru) 2021-02-02
RU2018135846A3 (pt) 2020-09-30
JP6992004B2 (ja) 2022-02-03
ZA201806864B (en) 2020-01-29
CA3020557A1 (en) 2017-11-02
US20170304267A1 (en) 2017-10-26
WO2017186686A1 (en) 2017-11-02
PT3448430T (pt) 2023-07-11
RU2018135846A (ru) 2020-05-26
BR112017026928B1 (pt) 2023-04-11
FI3448430T3 (fi) 2023-06-20
PL3448430T3 (pl) 2023-08-21
AU2017256623B2 (en) 2022-07-21
KR20180133869A (ko) 2018-12-17
AU2017256623A1 (en) 2018-11-01
IL262546B (en) 2022-05-01
EP3448430B1 (en) 2023-06-07
RS64307B1 (sr) 2023-07-31
MX2018013031A (es) 2019-01-17
IL262546A (en) 2018-12-31
CN109069650A (zh) 2018-12-21
SG11201809297UA (en) 2018-11-29
CA3020557C (en) 2024-05-21
KR102473545B1 (ko) 2022-12-01
EP3448430A1 (en) 2019-03-06
ES2949288T3 (es) 2023-09-27

Similar Documents

Publication Publication Date Title
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112018005768A2 (pt) sistemas de auxiliar implantável para determinar a inclinação do auxiliar
AR111208A1 (es) ANTICUERPOS ANTI-PÉPTIDO b AMILOIDE N3PGLU Y SUS USOS
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
PH12015502788A1 (en) Antibody formulations and methods
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112016010422A8 (pt) suplemento dietético, e uso de uma composição
MD20170020A2 (ro) Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
BR112016029675A2 (pt) dispositivos dilatadores nasais
BR112012033388A2 (pt) compostos para o tratamento de distúrbios e doenças de segmento posterior
BR112016025470A2 (pt) ?hdl terapêutico?
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112019004513A2 (pt) usos de um inibidor de lisil oxidase-like 2
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112015008143A2 (pt) complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112017026928A2 (pt) uso de um inibidor de acetilcolinesterase e idalopirdina para redução de quedas em pacientes com doença de parkinson
BR112018068817A2 (pt) beta-caseínas e função cognitiva
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2017, OBSERVADAS AS CONDICOES LEGAIS